An investigator-initiated clinical study of GPN02006 developed by Grand Pharmaceutical Group (HKG:0512) in cooperation with two other parties for the diagnosis of hepatocellular carcinoma recently achieved a milestone breakthrough, a Tuesday Hong Kong bourse filing said.
The clinical results showed the drug exhibits "excellent" safety and imaging efficacy, as well as high-quality imaging 30 minutes post administration.
The drug was developed in cooperation with Wuhan Ruidifu Biotechnology and JECHO Biopharmaceuticals.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.